Abstract:Purpose The main purpose of this paper is to identify and rank various barriers to pharmacovigilance (PV) in context of emerging economies and examine their interrelationships using the interpretive structural modeling (ISM) approach. The result is a model that offers insights about how to achieve rational and safe use of medicines and ensure patient safety as realized through robust national PV systems. Design/methodology/approach The paper develops a model to analyze the interactions among PV barriers using the ISM approach. Based on input from clinical and medical product development experts, PV barriers in emerging economies were identified and reviewed. The hierarchical interrelationships among these PV barriers were analyzed in context of their driving/dependence powers. Findings Findings of the study identify key PV barriers—lack of resources/infrastructure, weak legislation, unfair burden of disease, lack of PV capacity, training, and enforcement authority—that drive, or strongly influence, other barriers and thwart implementation of robust national PV systems in emerging economies. Pharmaceutical industry factors were PV barriers that were identified as autonomous, implying their relative disconnection from other barriers, and patient PV practices barrier was strongly dependent on other barriers. Research limitations/implications The paper offers policy- and decision-makers alike with a framework to support further research into interdependencies among key PV barriers in emerging economies. It can serve as an impetus for further research with potential to broadening the understanding of how and why PV systems may be rendered ineffective. Future studies can be planned to apply the ISM approach to study PV barriers in the context of developed economies and draw lessons and implications for policy- and decision-makers by contrasting results from these studies. Practical implications This paper contributes to the understanding of the multifaceted nature of PV and its barriers. The proposed approach gives public health decision-makers a better comprehension of driver PV barriers that have most influence on others versus dependent PV barriers, which are most influenced by others. Also, knowledge, attitude and practices of patients and caregivers can also be critical PV barriers in emerging economies. This information can be instrumental for public health policymakers, government entities, and health/PV practitioners to identify the PV barriers that they should prioritize for improvement and how to manage trade-offs between these barriers. Social implications PV barriers in emerging economies, as compared to developed economies, are inherently different and need to be examined in their specific context. The hierarchical ISM model suggests that resources and regulation initiatives by governments in emerging economies lead to through informed/enabled pharmaceutical supply chain players and eventually drive PV-specific knowledge, attitude, and practice outcomes improvements across their populace. Originality/value This paper highlights the deployment of ISM approach as a health policy decision support tool in the identifying and ranking barriers to effective PV systems in emerging economies, in terms of their contextual relationships, to achieve a better understanding as to how these interrelationships can affect national PV system outcomes.

A drug procurement, storage and distribution model in public hospitals in a developing country

A dynamic management model for sustainable drug supply chain in hospital pharmacies in Iran

Toward health system strengthening in low- and middle-income countries: insights from mathematical modeling of drug supply chains

Understanding public drug procurement in India: a comparative qualitative study of five Indian states

Inflated medicine prices in Vietnam: a qualitative study

Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country

A public-health approach to site-specific formulary management: addressing deficient drug supplies in Malawi

Implementation of Telepharmacy to Provide Medication Consultation Service for Patients: A Case Study From Thu Duc City Hospital, Ho Chi Minh City

[Centralized purchasing of essential drugs, a priority for the health care systems of developing countries]

Evaluation of Current Status of Newly Established Model Pharmacies in Bangladesh

Quality assurance of medicines supplied to low-income and middle-income countries: poor products in shiny boxes?

Evaluating Supply Chain Management Models for Third Party Logistics Operated Supply Processing Distribution in Thai Hospitals: An Analytical Hierarchy Fuzzy TOPSIS Approach

Study on the Working Model of Drug Dispensing Center Based on the Hospital Information System

The Resilience of Supply Chain: The Case of Vietnamese Pharmaceutical Companies

Supply Chain Management Perspective on Shortages in Drugs Sourcing

Practical 'modular design' research of emergency drug supplies in hospitals

Analysis of Drug Availability Management at the Regional General Hospital Pharmacy Installation

Perception of learners on the effectiveness and suitability of MyDispense: a virtual pharmacy simulation and its integration in the clinical pharmacy module in Viet Nam

Effectiveness of Supply Chain Planning in Ensuring Availability of CD/NCD Drugs in Non-Metropolitan and Rural Public Health System

Pharmacovigilance in emerging economies: modeling interaction among barriers

Analysis and discussion on the pharmaceutical centralized procurement implementation — a case study of a large provincial hospital in China